33 Acute Myeloid Leukemia Clinical Trials in Duarte, CA (2026)

Q: How do I join a clinical trial in Duarte?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Duarte research site will contact you.

Recruiting Acute Myeloid Leukemia Studies in Duarte

NCT04293562Recruiting

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia...

Duarte, CAPHASE31,400 participantsChildren's Oncology Group

View Study Details

NCT06976736Recruiting

A Long Term Follow-up Study of TScan TCR-T Products

The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-001 study. Participants will be monitored f...

Duarte, CA1,000 participantsTScan Therapeutics, Inc.

View Study Details

NCT07581002Recruiting

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (the spongy tissue inside the ...

Duarte, CAPHASE2660 participantsAbbVie

View Study Details

NCT06852222Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukem...

Duarte, CAPHASE3600 participantsJanssen Research & Development, LLC

View Study Details

NCT07211958Recruiting

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study ...

Duarte, CAPHASE3468 participantsSyndax Pharmaceuticals

View Study Details

NCT05429632Recruiting

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

This is a multi-center, randomized, double-blinded, placebo controlled trial....

Duarte, CAPHASE3366 participantsPriothera SAS

View Study Details

NCT06423911Recruiting

Study of Olverembatinib (HQP1351) in Patients With CP-CML

A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)...

Duarte, CAPHASE3333 participantsAscentage Pharma Group Inc.

View Study Details

NCT03802695Recruiting

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transpla...

Duarte, CAPHASE1300 participantsOrca Biosystems, Inc.

View Study Details

NCT02074839Recruiting

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mu...

Duarte, CAPHASE1291 participantsInstitut de Recherches Internationales Servier

View Study Details

NCT05436418Recruiting

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Background: Blood cancers (such as leukemias or lymphomas) often do not respond to standard treatments. A transplant of blood stem cells from a healthy donor can help people with these cancers. Somet...

Duarte, CAPHASE1260 participantsNational Cancer Institute (NCI)

View Study Details

NCT03850574Recruiting

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelod...

Duarte, CAPHASE1240 participantsAptose Biosciences Inc.

View Study Details

NCT04588922Recruiting

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies

SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation grou...

Duarte, CAPHASE1160 participantsSellas Life Sciences Group

View Study Details

NCT06969430Recruiting

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

The primary purpose of Phase 1 is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development (Dose optimization). The primary obj...

Duarte, CAPHASE1154 participantsDebiopharm International SA

View Study Details

NCT06533761Recruiting

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor effi...

Duarte, CAPHASE1125 participantsStelexis BioSciences

View Study Details

NCT06549790Recruiting

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Le...

Duarte, CAPHASE1124 participantsNerviano Medical Sciences

View Study Details

NCT04243785Recruiting

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory...

Duarte, CAPHASE180 participantsEdgewood Oncology Inc.

View Study Details

NCT03113643Recruiting

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS. The interventions involved in this study are: * SL-401 * Azacitidine * Venetoclax...

Duarte, CAPHASE172 participantsDana-Farber Cancer Institute

View Study Details

NCT06846606Recruiting

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinica...

Duarte, CAPHASE169 participantsAuron Therapeutics, Inc.

View Study Details

NCT06146257Recruiting

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or...

Duarte, CAPHASE148 participantsGluBio Therapeutics Inc.

View Study Details

NCT07020533Recruiting

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremi...

Duarte, CAPHASE146 participantsCity of Hope Medical Center

View Study Details

NCT06498973Recruiting

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

This phase Ib trial tests the safety, side effects, best dose and effectiveness of tagraxofusp in combination with azacitidine as maintenance therapy in treating patients with CD123 positive acute mye...

Duarte, CAPHASE143 participantsCity of Hope Medical Center

View Study Details

NCT07751991Recruiting

A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

The goal of this study is to evaluate the safety of CHM-029, an investigational oral medicine, and to evaluate its activity in treating certain types of acute myeloid leukemia (AML) in adults. The mai...

Duarte, CAPHASE140 participantsCharm Therapeutics

View Study Details

NCT06552416Recruiting

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

This study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per...

Duarte, CAPHASE140 participantsMarker Therapeutics, Inc.

View Study Details

NCT07582172Recruiting

Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

This phase II trial tests the effect of total marrow and lymphoid irradiation (TMLI) in combination with fludarabine and melphalan as conditioning regimen in older patients with acute myeloid leukemia...

Duarte, CAPHASE235 participantsCity of Hope Medical Center

View Study Details

NCT05101551Recruiting

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

This is a Phase 1, open label, multicenter, dose finding study with dose expansion intended to evaluate the safety and tolerability of talazoparib in combination with conventional chemotherapy. Prelim...

Duarte, CAPHASE134 participantsNorman J. Lacayo

View Study Details

NCT05263284Recruiting

8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and best dose of a new 8-chloroadenosine in combination with venetoclax in treating patients with acute myeloid leukemia that has come back (relapsed...

Duarte, CAPHASE130 participantsCity of Hope Medical Center

View Study Details

NCT07250646Recruiting

A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

The purpose of this study is to test the safest and most effective dose of a new investigational drug, rebecsinib. Participants in this study will have either Secondary Acute Myeloid Leukemia (sAML) t...

Duarte, CAPHASE128 participantsAspera Biomedicines, Inc.

View Study Details

NCT05672147Recruiting

CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and the best dose of anti-CD33 chimeric antigen receptor (CAR) T-Cell therapy in treating patients with acute myeloid leukemia that has come back (re...

Duarte, CAPHASE127 participantsCity of Hope Medical Center

View Study Details

NCT07025564Recruiting

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and best dose of miRisten in treating patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or that ...

Duarte, CAPHASE120 participantsCity of Hope Medical Center

View Study Details

NCT07613385Recruiting

Individualized AML Treatment

Every patient responds differently to their cancer treatment, and some treatments work better for some patients more than others. For patients with relapsed, refractory ( R/R) AML, there may be fewer ...

Duarte, CA20 participantsCity of Hope Medical Center

View Study Details

NCT06543381Recruiting

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

This phase I trial tests the safety, side effects, and effectiveness of olutasidenib in preventing the return of disease (relapse) in patients who have undergone donor (allogeneic) hematopoietic cell ...

Duarte, CAPHASE115 participantsCity of Hope Medical Center

View Study Details

NCT06996119Recruiting

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (...

Duarte, CAPHASE115 participantsCity of Hope Medical Center

View Study Details

NCT06763341Recruiting

A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

This phase 1 trial tests safety, side effects, and best dose of AOH1996 for the treatment of patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or A...

Duarte, CAPHASE112 participantsCity of Hope Medical Center

View Study Details

About Acute Myeloid Leukemia Clinical Trials in Duarte

Acute myeloid leukemia (AML) is a fast-growing cancer of the blood and bone marrow characterized by abnormal myeloid cells. It is the most common acute leukemia in adults. Treatment typically includes intensive chemotherapy and may involve stem cell transplant.

There are currently 33 acute myeloid leukemia clinical trials recruiting participants in Duarte, CA. These studies are seeking a combined 7,155 participants. Research is being sponsored by Children's Oncology Group, TScan Therapeutics, Inc., AbbVie and 21 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Acute Myeloid Leukemia Clinical Trials in Duarte — FAQ

Are there acute myeloid leukemia clinical trials in Duarte?

Yes, there are 33 acute myeloid leukemia clinical trials currently recruiting in Duarte, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Duarte?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Duarte research site will contact you about next steps.

Are clinical trials in Duarte free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Duarte studies also compensate for your time and travel.

What acute myeloid leukemia treatments are being tested?

The 33 active trials in Duarte are testing new therapies including novel drugs, biologics, and treatment approaches for acute myeloid leukemia.

Data updated October 18, 2026 from ClinicalTrials.gov